Oral immunotherapy–induced gastrointestinal symptoms and peripheral blood eosinophil responses - 19/04/17
Doi : 10.1016/j.jaci.2016.09.053
Michael R. Goldberg, MD, PhD a 
, Arnon Elizur, MD a, b, Liat Nachshon, MD a, Michael Y. Appel, PhD a, Michael B. Levy, MD a, Keren Golobov, BScNutr, RD a, Robert Goldberg, PhD c, Miguel Stein, MD d, Marc E. Rothenberg, MD, PhD e, Yitzhak Katz, MD a, b
, Arnon Elizur, MD a, b, Liat Nachshon, MD a, Michael Y. Appel, PhD a, Michael B. Levy, MD a, Keren Golobov, BScNutr, RD a, Robert Goldberg, PhD c, Miguel Stein, MD d, Marc E. Rothenberg, MD, PhD e, Yitzhak Katz, MD a, b a Allergy, Immunology and Pediatric Pulmonary Institute, “Assaf-Harofeh” Medical Center, Zerifin, Israel
b Department of Pediatrics, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
c Department of Computer Science, City University of New York, New York, NY
d Allergy and Immunology Unit, E. Wolfson Medical Center, Holon, Israel
e Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| M.R.G. is funded by a Kamea grant from the Ministry of Health, Israel. Y.K. is supported by the Leon Alcalay Chair in Pediatric Immunology, Tel Aviv University. |
|
| Disclosure of potential conflict of interest: M. E. Rothenberg's institution has received a grant from the National Institutes of Health, US-Israel Binational Grant, Patient-Centered Outcomes Research Institute (PCORI), and patents from Miraca Life Sciences. M. E. Rothenberg has received consultancy fees from Receptos, Immune Pharmaceuticals, NKT Therapeutics, and PulmOne Therapeutics; has received consultancy fees from Merck; has received royalties from Teva Pharmaceuticals and stock options from PulmOne, NKT Therapeutics, and Immune Pharmaceuticals; has an equity interest in reslizumab (Teva Pharmaceuticals); and is the inventor of several eosinophilic esophagitis–related patents owned by Cincinnati Children's Hospital Medical Center. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2016
American Academy of Allergy, Asthma & Immunology. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Vol 139 - N° 4
P. 1388 - avril 2017 Regresar al número
Artículo precedente
- Association of ORAI1 gene polymorphisms with chronic spontaneous urticaria and the efficacy of the nonsedating H1 antihistamine desloratadine
- Jie Li, Aiyuan Guo, Wangqing Chen, Lianghua Bin, Yijing He, Wu Zhu, Cong Peng, Siyu Yan, Mingliang Chen, Jianglin Zhang, Juan Su, Mei Yi, Zhaoqian Liu, Wei Zhang, Weiqi Zeng, Donald Y.M. Leung, Xiang Chen
- Combined immunodeficiency and hypoglycemia associated with mutations in hypoxia upregulated 1
- Emma M. Haapaniemi, Christopher L. Fogarty, Salla Keskitalo, Shintaro Katayama, Helena Vihinen, Mette Ilander, Satu Mustjoki, Kaarel Krjutškov, Markku Lehto, Timo Hautala, Ove Eriksson, Eija Jokitalo, Vidya Velagapudi, Markku Varjosalo, Mikko Seppänen, Juha Kere
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?